Revenue: As of FY2026 Q1, the actual value is USD 1.996 M, beating the estimate of USD 1.322 M.EPS: As of FY2026 Q1, the actual value is USD -0.15, beating the estimate of USD -0.1578.EBIT: As of FY2026 Q1, the actual value is USD -23.71 M.Aclaris Therapeutics, Inc. operates as one reportable segment focused on immuno-inflammatory diseases, generating revenue through intellectual property licensing and laboratory services .<h4>Revenue</h4><ul><li>Total Revenue: Increased to $1,996 thousand for the three months ended March 31, 2026, from $1,455 thousand for the same period in 2025 .</li><li>Contract Research Revenue: Rose to $537 thousand in Q1 2026 from $445 thousand in Q1 2025, driven by higher billed hours, partially offset by a lower average billing rate .</li><li>Licensing Revenue: Increased to $1,459 thousand in Q1 2026 from $1,010 thousand in Q1 2025, attributed to higher royalties from the Lilly and Sun Pharma license agreements .</li></ul><h4>Operational Metrics</h4><ul><li>Net Loss: The net loss was -$19,824 thousand for the three months ended March 31, 2026, compared to -$15,085 thousand for the same period in 2025 .</li><li>Loss from Operations: Increased to -$22,192 thousand in Q1 2026 from -$18,084 thousand in Q1 2025 .</li><li>Total Costs and Expenses: Increased to $24,188 thousand in Q1 2026 from $19,539 thousand in Q1 2025 .<ul><li>Cost of Revenue: Decreased to $395 thousand in Q1 2026 from $506 thousand in Q1 2025, primarily due to lower personnel-related costs .</li><li>Research and Development (R&amp;D) Expenses: Increased to $15,657 thousand in Q1 2026 from $11,584 thousand in Q1 2025 .</li><li>General and Administrative (G&amp;A) Expenses: Increased to $6,743 thousand in Q1 2026 from $6,139 thousand in Q1 2025 .</li><li>Licensing Expenses: Increased to $1,393 thousand in Q1 2026 from $1,010 thousand in Q1 2025, due to higher royalties earned under license agreements .</li><li>Revaluation of Contingent Consideration: Was $0 in Q1 2026, down from $300 thousand in Q1 2025 .</li></ul></li><li>Other Income: Total other income was $2,368 thousand in Q1 2026, down from $2,999 thousand in Q1 2025 .<ul><li>Interest Income: Decreased to $1,514 thousand in Q1 2026 from $2,166 thousand in Q1 2025, due to a lower average investment balance and lower interest rates .</li><li>Non-cash Royalty Income: Remained consistent at $854 thousand in Q1 2026 and $833 thousand in Q1 2025, related to the sale of OLUMIANT® royalty payments .</li></ul></li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: Increased to -$18,149 thousand in Q1 2026 from -$13,057 thousand in Q1 2025, primarily due to higher net losses after non-cash adjustments .</li><li>Net Cash Used In Investing Activities: Changed from a net cash provided of $19,119 thousand in Q1 2025 to a net cash used of -$30,932 thousand in Q1 2026, mainly due to greater purchases of marketable securities and lower proceeds from sales and maturities .</li><li>Net Cash Provided by Financing Activities: Increased to $57,781 thousand in Q1 2026 from -$275 thousand in Q1 2025, primarily due to proceeds from at-the-market common stock sales .</li><li>Cash and Cash Equivalents: Ended Q1 2026 at $28,660 thousand, up from $19,960 thousand at December 31, 2025 .</li></ul><h4>Unique Metrics</h4><ul><li>Accumulated Deficit: As of March 31, 2026, the accumulated deficit was -$987.6 million .</li><li>Contingent Consideration Liability: Remained at $11.0 million as of March 31, 2026 and December 31, 2025 .</li><li>Marketable Securities: Totaled $162.1 million as of March 31, 2026, compared to $131.4 million as of December 31, 2025 .</li><li>Stock-based Compensation Expense: Totaled $3,198 thousand in Q1 2026, down from $3,535 thousand in Q1 2025 .</li></ul><h4>Future Outlook and Strategy</h4>Aclaris Therapeutics, Inc. expects to incur significant net losses and operating expenses as it advances its product candidates through development, aiming to finance operations through equity sales, non-dilutive financing, and potential partnerships . The company believes its current cash, cash equivalents, and marketable securities are sufficient to fund operating and capital expenditure requirements for over 12 months from the financial statement issuance date . Key product development timelines include top-line data for Bosakitug in Q4 2026, initiation of a Phase 2b study for ATI-2138 in H2 2026, top-line data for ATI-052 in H2 2026, and an IND filing for ATI-9494 in H2 2026 .

Aclaris Therap | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 1.996 M